BEAMSTART Logo

In Post-Theranos Era, Epi One's Transparent Approach to Cancer Detection Wins Investor Trust

GlobeNewswire LogoGlobeNewswire10h ago

In Post-Theranos Era, Epi One's Transparent Approach to Cancer Detection Wins Investor Trust - GlobeNewswire

Quick Summary:

Epi One's proprietary genomic technology achieves 95% accuracy in preliminary tests, offering hope for earlier, more affordable cancer detection.New York, NY, Oct.04, 2024 (GLOBE NEWSWIRE) -- In a world still reeling from the Theranos scandal, a new beacon of hope in cancer detection is rising – and this time, it's inviting the world to look under the microscope.  Epi One, a biotech startup born from personal tragedy and scientific rigor, has captivated investors and the medical community alike, surpassing $1.2 million in crowdfunding on StartEngine.

A Team Built for Success Epi One boasts a leadership team with exceptional credentials and experience in oncology, genomics, and business leadership: Michael Marquardt, CEO and Board Member: Former American Cancer Society Board Chair, Michael brings extensive experience in tech and healthcare leadership to Epi One.

This powerhouse team combines world-class scientific expertise with proven business leadership, positioning Epi One at the forefront of cancer detection technology.

or

Article Details

Author / Journalist: Epi One

Category: Technology

Markets:

Topics:

Source Website Secure: Yes (HTTPS)

News Sentiment: Positive

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-10-04 @ 19:00:00 (10 hours ago)

News Timezone: GMT +8:00

News Source URL: globenewswire.com

Language: English

Article Length: 807 words

Reading Time: 5 minutes read

Sentences: 38 lines

Sentence Length: 22 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © GlobeNewswire

News ID: 22885661

View Article Analysis

About GlobeNewswire

Main Topics: Technology

Official Website: globenewswire.com

Update Frequency: 28 posts per day

Year Established: 1998

Headquarters: China

News Last Updated: 9 hours ago

Coverage Areas: China

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #116

Publisher Details

Frequently Asked Questions

How long will it take to read this news story?

The story "In Post-Theranos Era, Epi One's Transparent Approach to Cancer Detection Wins Investor Trust" has 807 words across 38 sentences, which will take approximately 4 - 7 minutes for the average person to read.

Which news outlet covered this story?

The story "In Post-Theranos Era, Epi One's Transparent Approach to Cancer Detection Wins Investor Trust" was covered 10 hours ago by GlobeNewswire, a news publisher based in China.

How trustworthy is 'GlobeNewswire' news outlet?

GlobeNewswire is a fully independent (privately-owned) news outlet established in 1998 that covers mostly technology news.

The outlet is headquartered in China and publishes an average of 28 news stories per day.

It's most recent story was published 9 hours ago.

What do people currently think of this news story?

The sentiment for this story is currently Positive, indicating that people regard this as "good news".

How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
  • News ID: #22885661
  • URL: https://beamstart.com/news/in-post-theranos-era-epi-17280685284759

BEAMSTART

BEAMSTART is a global entrepreneurship community, serving as a catalyst for innovation and collaboration. With a mission to empower entrepreneurs, we offer exclusive deals with savings totaling over $1,000,000, curated news, events, and a vast investor database. Through our portal, we aim to foster a supportive ecosystem where like-minded individuals can connect and create opportunities for growth and success.

© Copyright 2024 BEAMSTART. All Rights Reserved.